Oxcarbazepine or Eslicarbazepine Metabolite (MHD)
0098834
Ordering Recommendation
Optimize drug therapy and monitor patient adherence.
Mnemonic
OXCARB
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-2 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
- Patient Preparation
- Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
- Collect
- Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2 EDTA).
- Specimen Preparation
- Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
- Remarks
- Stability
- After separation from cells: Ambient: 6 weeks; Refrigerated: 6 weeks; Frozen: 3 months (avoid repeated freeze/thaw cycles)
Reference Interval
Effective November 18, 2013
| Therapeutic Range: | 3-35 µg/mL |
| Toxic: | Greater than 40 µg/mL |
Interpretive Data
This test measures monohydroxyoxcarbazepine (MHD). Adverse effects may include dizziness, fatigue, nausea, headache, somnolence, ataxia and tremor.
Note
CPT Code(s)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0098834 | Oxcarb or Eslicarb Metabolite (MHD) | 31019-3 |
Aliases
- 10-Hydroxy-10,11-Dihydrocarbamazepine
- 10-Hydroxycarbazepine
- 10-OH-Carbazepine (MHD)
- 11-Dihydrocarbamazepine
- Eslicarbazepine
- GP 47680
- Metabolite of Oxcarbazepine
- MHC
- MHD
- Monohydroxy Carbamazepine
- Monohydroxy Carbamazepine (MHD)
- Oxcarbazepine
- Oxcarbazepine Metabolite
- Oxcarbazepine Metabolite, 10-Hydroxy-10
- Trileptal (Parent Pro-Drug)